See our Annual Report for the year 2024 for detailed updates on our pipeline candidates.

Pipeline

Breakthrough technologies to revolutionize medicine

2 pan-tumor priority programs

Explore our priority programs

20+ phase 2 and phase 3 clinical trials in oncology

Explore mid- to late-stage clinical trials

€2.25 bn investment into R&D in 2024

Explore our diversified pipeline

Stay up to date

Sign up for our email alert for news on our growing pipeline